GLP-1 vs Tirzepatide: Complete Head-to-Head Comparison
SURMOUNT-1 and STEP 1 were never run against each other, so most comparisons are cross-trial and imprecise. SURMOUNT-5 finally provided a direct head-to-head. This guide separates what has actually been measured from what gets extrapolated.
Mechanism: One Receptor vs Two
Semaglutide is a GLP-1 receptor agonist. Tirzepatide activates both GLP-1 and GIP receptors. GIP contributes to insulin secretion and appears to modulate adipose tissue handling and nausea signaling — which is part of why tirzepatide can deliver larger weight loss without proportionally worse gastrointestinal tolerability.
Efficacy: The Numbers
STEP 1 reported −14.9% for semaglutide 2.4 mg at 68 weeks. SURMOUNT-1 reported −20.9% for tirzepatide 15 mg at 72 weeks. SURMOUNT-5, the direct head-to-head in adults with obesity, reported roughly −20.2% for tirzepatide versus −13.7% for semaglutide at 72 weeks — a consistent advantage of about six to seven percentage points.
Cost Reality
List prices are close, but real-world cost depends almost entirely on coverage. With commercial insurance covering an obesity indication, both can land under $100/month. Without coverage, cash prices commonly run $400–1,500/month for tirzepatide and $200–1,300/month for semaglutide depending on manufacturer direct programs and compounded availability. Cost, not efficacy, drives most switching decisions.
Side Effect Comparison
Both are dominated by gastrointestinal effects during titration. Nausea rates ran roughly 44% in STEP 1 versus 29–39% across tirzepatide dose groups in SURMOUNT-1. Constipation, diarrhea and vomiting are common to both. Serious event rates were low and broadly similar. Individual tolerance varies enough that trial averages are weak predictors for one person.
Decision Matrix: Which to Choose
There is no universally better option — there is a better fit for a given goal, budget and history.
Verification Checklist for Either Molecule
Whichever you use, the same failure modes apply: substituted molecule, underdosed concentration, degraded product from cold-chain failure, or a fabricated certificate of analysis. Photograph the label and lot number before first dose, keep the COA, and confirm concentration matches what you were prescribed.
Frequently Asked Questions
Is tirzepatide better than semaglutide?
For weight loss magnitude, the direct head-to-head SURMOUNT-5 trial favored tirzepatide by roughly six to seven percentage points. Semaglutide currently has stronger published cardiovascular outcome data.
Can you switch between them?
Yes, switching is common and usually restarts at a low dose with re-titration. It is a prescriber decision, not a self-managed one.
Which has fewer side effects?
Reported nausea rates were lower with tirzepatide despite greater weight loss, but the overall adverse event profiles are similar and individual variation is large.
References
Report a Safety Issue
If you've experienced health issues after using this peptide, please report it. Your report helps us track safety issues and protect other users.
Report Adverse Event